UBS Raises price Target on Foundation Medicine (FMI) to $22
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
UBS reiterated a Neutral rating on Foundation Medicine (NASDAQ: FMI), and raised the price target to $22.00 (from $16.00), following the company's announced expanded Local Coverage Determination.
Analyst Jonathan Groberg commented, "Palmetto, a Medicare contractor, announced last Thursday an expanded Local Coverage Determination (LCD) to include all stage IIIB/IV non-small cell lung cancer (NSCLC) patients. This new policy now provides coverage for comprehensive genomic profiling (CGP) for metastatic NSCLC patients who have not been tested for genomic mutations or who have tested negative for EGFR mutations. This is important for patients as CGP detected alterations may indicate eligibility for targeted treatment or immunotherapy."
Shares of Foundation Medicine closed at $23.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Susquehanna Cuts Price Target on KLA-Tencor (KLAC) Following Strong 1Q
- Jefferies Remains Sidelined on FirstEnergy (FE) After Adjusting Forecast
- Piper Jaffray Cuts PT on Inovio Pharma (INO) to $13 Following FDA Clinical Hold; Affirms at 'Overweight'
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!